A Review of Pharma Stocks’ EPS Growth Rates
In this article, we’ll compare the EPS growth rates of Eli Lilly (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
Sept. 18 2018, Updated 10:31 a.m. ET
EPS growth rates
In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
The chart above compares the EPS growth rates of these companies since the first quarter of 2017.
Eli Lilly
Eli Lilly reported a ~35.1% rise in its EPS in the second quarter. Its adjusted EPS rose to $1.50 in the quarter compared to its EPS of $1.11 in the second quarter of 2017.
Pfizer
Pfizer reported a ~20.9% rise in its EPS in the second quarter. Its adjusted EPS rose to $0.81 in the quarter compared to its EPS of $0.67 in the second quarter of 2017.
Merck & Co.
Merck & Co. reported a ~4.9% rise in its EPS in the second quarter. Its adjusted EPS rose to $1.06 in the quarter compared to its EPS of $1.01 in the second quarter of 2017.
Allergan
Allergan reported a ~9.9% rise in its EPS in the second quarter. Its adjusted EPS rose to $4.42 in the quarter compared to its EPS of $4.02 in the second quarter of 2017.
GlaxoSmithKline
GlaxoSmithKline reported a ~3.3% rise in its EPS in the second quarter. Its adjusted EPS rose to 28.10 British pence in the quarter compared to its EPS of 27.20 pence in the second quarter of 2017.
We’ll discuss the quarterly revenue performances of and 2018 estimates for each of these companies in the coming articles.
The iShares US Healthcare ETF (IHE) holds 6.9% in Eli Lilly, 9.3% in Pfizer, 8.2% in Merck & Co., and 5.7% in Allergan.
